393 related articles for article (PubMed ID: 36509071)
1. Physician Awareness of Immune-Related Adverse Events of Immune Checkpoint Inhibitors.
Khalid AB; Calderon G; Jalal SI; Durm GA
J Natl Compr Canc Netw; 2022 Dec; 20(12):1316-1320. PubMed ID: 36509071
[TBL] [Abstract][Full Text] [Related]
2. Immune Checkpoint Inhibitors and Immune-Related Adverse Events in Patients With Advanced Melanoma: A Systematic Review and Network Meta-analysis.
Chang CY; Park H; Malone DC; Wang CY; Wilson DL; Yeh YM; Van Boemmel-Wegmann S; Lo-Ciganic WH
JAMA Netw Open; 2020 Mar; 3(3):e201611. PubMed ID: 32211869
[TBL] [Abstract][Full Text] [Related]
3. An Investigation of Nine Patients with Gastrointestinal Immune-Related Adverse Events Caused by Immune Checkpoint Inhibitors.
Miyahara K; Noda T; Ito Y; Hidaka H; Fujimoto S; Takedomi H; Akutagawa T; Sakata Y; Shimamura T; Tominaga N; Yamaguchi D; Fujimoto K
Digestion; 2020; 101(1):60-65. PubMed ID: 31801131
[TBL] [Abstract][Full Text] [Related]
4. Immune-related adverse events associated with immune checkpoint inhibitors: An updated comprehensive disproportionality analysis of the FDA adverse event reporting system.
Chen C; Wu B; Zhang C; Xu T
Int Immunopharmacol; 2021 Jun; 95():107498. PubMed ID: 33725634
[TBL] [Abstract][Full Text] [Related]
5. Chronic immune-related adverse events in patients with cancer receiving immune checkpoint inhibitors: a systematic review.
Barron CC; Stefanova I; Cha Y; Elsolh K; Zereshkian A; Gaafour N; McWhirter E
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37536939
[TBL] [Abstract][Full Text] [Related]
6. Management of Immune Checkpoint Inhibitor Toxicities: A Review and Clinical Guideline for Emergency Physicians.
Hryniewicki AT; Wang C; Shatsky RA; Coyne CJ
J Emerg Med; 2018 Oct; 55(4):489-502. PubMed ID: 30120013
[TBL] [Abstract][Full Text] [Related]
7. Safety of COVID-19 vaccines in subjects with solid tumor cancers receiving immune checkpoint inhibitors.
Gilbert D; Hu J; Medina T; Kessler ER; Lam ET
Hum Vaccin Immunother; 2023 Dec; 19(1):2207438. PubMed ID: 37157982
[TBL] [Abstract][Full Text] [Related]
8. Immune Checkpoint Inhibitor-Associated Primary Adrenal Insufficiency: WHO VigiBase Report Analysis.
Grouthier V; Lebrun-Vignes B; Moey M; Johnson DB; Moslehi JJ; Salem JE; Bachelot A
Oncologist; 2020 Aug; 25(8):696-701. PubMed ID: 32390168
[TBL] [Abstract][Full Text] [Related]
9. Real-World Clinical and Economic Outcomes in Selected Immune-Related Adverse Events Among Patients with Cancer Receiving Immune Checkpoint Inhibitors.
Zheng Y; Kim R; Yu T; Gayle JA; Wassel CL; Dreyfus J; Phatak H; George S
Oncologist; 2021 Nov; 26(11):e2002-e2012. PubMed ID: 34327774
[TBL] [Abstract][Full Text] [Related]
10. Real-World Adherence to Toxicity Management Guidelines for Immune-Related Adverse Events.
Teimouri A; Minard LV; Scott SN; Daniels A; Snow S
Curr Oncol; 2022 Apr; 29(5):3104-3117. PubMed ID: 35621642
[TBL] [Abstract][Full Text] [Related]
11. Patterns of toxicity burden for FDA-approved immune checkpoint inhibitors in the United States.
Yang F; Shay C; Abousaud M; Tang C; Li Y; Qin Z; Saba NF; Teng Y
J Exp Clin Cancer Res; 2023 Jan; 42(1):4. PubMed ID: 36600271
[TBL] [Abstract][Full Text] [Related]
12. Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - A systematic review and meta-analysis.
Hussaini S; Chehade R; Boldt RG; Raphael J; Blanchette P; Maleki Vareki S; Fernandes R
Cancer Treat Rev; 2021 Jan; 92():102134. PubMed ID: 33302134
[TBL] [Abstract][Full Text] [Related]
13. Impact of Selective Immunosuppressive Therapy on Subsequent Immune-Related Adverse Events After Immune Checkpoint Inhibitor-Induced Colitis Treatment.
Pizuorno Machado A; Shatila M; Glitza Oliva IC; Altan M; Siddiqui B; Zhou Y; Varatharajalu K; Zhang HC; Thomas A; Wang Y
Am J Clin Oncol; 2023 Aug; 46(8):360-365. PubMed ID: 37219360
[TBL] [Abstract][Full Text] [Related]
14. Immune-related adverse events and immune checkpoint inhibitor tolerance on rechallenge in patients with irAEs: a single-center experience.
Bhatlapenumarthi V; Patwari A; Harb AJ
J Cancer Res Clin Oncol; 2021 Sep; 147(9):2789-2800. PubMed ID: 33774736
[TBL] [Abstract][Full Text] [Related]
15. Immune checkpoint inhibitor-induced pure red cell aplasia: Case series and large-scale pharmacovigilance analysis.
Guo Q; Gao J; Guo H; Xie J; Cheng J
Int Immunopharmacol; 2023 Jan; 114():109490. PubMed ID: 36459923
[TBL] [Abstract][Full Text] [Related]
16. Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors.
Pavan A; Calvetti L; Dal Maso A; Attili I; Del Bianco P; Pasello G; Guarneri V; Aprile G; Conte P; Bonanno L
Oncologist; 2019 Aug; 24(8):1128-1136. PubMed ID: 31015312
[TBL] [Abstract][Full Text] [Related]
17. Severe neuromuscular immune-related adverse events of immune checkpoint inhibitors at national cancer center in Korea.
Hyun JW; Kim KH; Kim SH; Kim HJ
J Cancer Res Clin Oncol; 2023 Aug; 149(9):5583-5589. PubMed ID: 36495331
[TBL] [Abstract][Full Text] [Related]
18. Immune-Related Adverse Events (irAEs): Diagnosis, Management, and Clinical Pearls.
Darnell EP; Mooradian MJ; Baruch EN; Yilmaz M; Reynolds KL
Curr Oncol Rep; 2020 Mar; 22(4):39. PubMed ID: 32200442
[TBL] [Abstract][Full Text] [Related]
19. Correlation between immune-related adverse events and prognosis in patients with various cancers treated with anti PD-1 antibody.
Matsuoka H; Hayashi T; Takigami K; Imaizumi K; Shiroki R; Ohmiya N; Sugiura K; Kawada K; Sawaki A; Maeda K; Ando Y; Uyama I
BMC Cancer; 2020 Jul; 20(1):656. PubMed ID: 32664888
[TBL] [Abstract][Full Text] [Related]
20. Management of immune related adverse events induced by immune checkpoint inhibition.
Teufel A; Zhan T; Härtel N; Bornschein J; Ebert MP; Schulte N
Cancer Lett; 2019 Aug; 456():80-87. PubMed ID: 31051213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
